163 related articles for article (PubMed ID: 16758204)
1. Lack of tumor recognition by cytolytic T lymphocyte clones recognizing peptide 195-203 encoded by gene MAGE-A3 and presented by HLA-A24 molecules.
So T; Hanagiri T; Chapiro J; Colau D; Brasseur F; Yasumoto K; Boon T; Coulie PG
Cancer Immunol Immunother; 2007 Feb; 56(2):259-69. PubMed ID: 16758204
[TBL] [Abstract][Full Text] [Related]
2. Analysis of individual specific cytotoxic T lymphocytes for two MAGE-3-derived epitopes presented by HLA-A24.
Katsura F; Eura M; Chikamatsu K; Oiso M; Yumoto E; Ishikawa T
Jpn J Clin Oncol; 2000 Mar; 30(3):117-21. PubMed ID: 10798537
[TBL] [Abstract][Full Text] [Related]
3. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1.
Chaux P; Luiten R; Demotte N; Vantomme V; Stroobant V; Traversari C; Russo V; Schultz E; Cornelis GR; Boon T; van der Bruggen P
J Immunol; 1999 Sep; 163(5):2928-36. PubMed ID: 10453041
[TBL] [Abstract][Full Text] [Related]
4. A newly identified MAGE-3-derived epitope recognized by HLA-A24-restricted cytotoxic T lymphocytes.
Oiso M; Eura M; Katsura F; Takiguchi M; Sobao Y; Masuyama K; Nakashima M; Itoh K; Ishikawa T
Int J Cancer; 1999 May; 81(3):387-94. PubMed ID: 10209953
[TBL] [Abstract][Full Text] [Related]
5. A newly identified MAGE-3-derived, HLA-A24-restricted peptide is naturally processed and presented as a CTL epitope on MAGE-3-expressing gastrointestinal cancer cells.
Miyagawa N; Kono K; Mimura K; Omata H; Sugai H; Fujii H
Oncology; 2006; 70(1):54-62. PubMed ID: 16446550
[TBL] [Abstract][Full Text] [Related]
6. Induction of antitumor cytotoxic T lymphocytes with a MAGE-3-encoded synthetic peptide presented by human leukocytes antigen-A24.
Tanaka F; Fujie T; Tahara K; Mori M; Takesako K; Sette A; Celis E; Akiyoshi T
Cancer Res; 1997 Oct; 57(20):4465-8. PubMed ID: 9377553
[TBL] [Abstract][Full Text] [Related]
7. Identification of a MAGE-2-encoded human leukocyte antigen-A24-binding synthetic peptide that induces specific antitumor cytotoxic T lymphocytes.
Tahara K; Takesako K; Sette A; Celis E; Kitano S; Akiyoshi T
Clin Cancer Res; 1999 Aug; 5(8):2236-41. PubMed ID: 10473111
[TBL] [Abstract][Full Text] [Related]
8. A new MAGE-4 antigenic peptide recognized by cytolytic T lymphocytes on HLA-A24 carcinoma cells.
Ottaviani S; Colau D; van der Bruggen P; van der Bruggen P
Cancer Immunol Immunother; 2006 Jul; 55(7):867-72. PubMed ID: 16151806
[TBL] [Abstract][Full Text] [Related]
9. Identification of novel MAGE-A6- and MAGE-A12-derived HLA-A24-restricted cytotoxic T lymphocyte epitopes using an in silico peptide-docking assay.
Akiyama Y; Komiyama M; Nakamura Y; Iizuka A; Oshita C; Kume A; Nogami M; Miyata H; Ashizawa T; Yoshikawa S; Kiyohara Y; Yamaguchi K
Cancer Immunol Immunother; 2012 Dec; 61(12):2311-9. PubMed ID: 22707303
[TBL] [Abstract][Full Text] [Related]
10. Characterization of a MAGE-1-derived HLA-A24 epitope-specific CTL line from a Japanese metastatic melanoma patient.
Akiyama Y; Maruyama K; Tai S; Komiyama M; Iizuka A; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
Anticancer Res; 2009 Feb; 29(2):647-55. PubMed ID: 19331215
[TBL] [Abstract][Full Text] [Related]
11. A MAGE-C2 antigenic peptide processed by the immunoproteasome is recognized by cytolytic T cells isolated from a melanoma patient after successful immunotherapy.
Ma W; Vigneron N; Chapiro J; Stroobant V; Germeau C; Boon T; Coulie PG; Van den Eynde BJ
Int J Cancer; 2011 Nov; 129(10):2427-34. PubMed ID: 21207413
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide.
Nishiyama T; Tachibana M; Horiguchi Y; Nakamura K; Ikeda Y; Takesako K; Murai M
Clin Cancer Res; 2001 Jan; 7(1):23-31. PubMed ID: 11205913
[TBL] [Abstract][Full Text] [Related]
13. Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients.
Valmori D; Liénard D; Waanders G; Rimoldi D; Cerottini JC; Romero P
Cancer Res; 1997 Feb; 57(4):735-41. PubMed ID: 9044853
[TBL] [Abstract][Full Text] [Related]
14. Induction of specific CTL by MAGE-3/CEA peptide-pulsed dendritic cells from HLA-A2/A24(+) gastrointestinal cancer patients.
Hao X; Shao Y; Ren X; Liu H; Xu Q; Li H; Zhang P; An X; Ren B
J Cancer Res Clin Oncol; 2002 Sep; 128(9):507-15. PubMed ID: 12242516
[TBL] [Abstract][Full Text] [Related]
15. The use of filamentous bacteriophage fd to deliver MAGE-A10 or MAGE-A3 HLA-A2-restricted peptides and to induce strong antitumor CTL responses.
Sartorius R; Pisu P; D'Apice L; Pizzella L; Romano C; Cortese G; Giorgini A; Santoni A; Velotti F; De Berardinis P
J Immunol; 2008 Mar; 180(6):3719-28. PubMed ID: 18322177
[TBL] [Abstract][Full Text] [Related]
16. Lysis of human chondrosarcoma cells by cytolytic T lymphocytes recognizing a MAGE-A3 antigen presented by HLA-A1 molecules.
Bluman EM; Coulie PG; Xiaojuan S; Machan J; Lin C; Meitner PA; Block JA; Terek RM
J Orthop Res; 2007 May; 25(5):678-84. PubMed ID: 17290408
[TBL] [Abstract][Full Text] [Related]
17. Analysis of a rare melanoma patient with a spontaneous CTL response to a MAGE-A3 peptide presented by HLA-A1.
Hanagiri T; van Baren N; Neyns B; Boon T; Coulie PG
Cancer Immunol Immunother; 2006 Feb; 55(2):178-84. PubMed ID: 16187089
[TBL] [Abstract][Full Text] [Related]
18. Identification of new antigenic peptide presented by HLA-Cw7 and encoded by several MAGE genes using dendritic cells transduced with lentiviruses.
Breckpot K; Heirman C; De Greef C; van der Bruggen P; Thielemans K
J Immunol; 2004 Feb; 172(4):2232-7. PubMed ID: 14764691
[TBL] [Abstract][Full Text] [Related]
19. A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes.
Schultz ES; Lethé B; Cambiaso CL; Van Snick J; Chaux P; Corthals J; Heirman C; Thielemans K; Boon T; van der Bruggen P
Cancer Res; 2000 Nov; 60(22):6272-5. PubMed ID: 11103782
[TBL] [Abstract][Full Text] [Related]
20. Generation of CTL recognizing an HLA-A*0201-restricted epitope shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 tumor antigens: implication in a broad-spectrum tumor immunotherapy.
Graff-Dubois S; Faure O; Gross DA; Alves P; Scardino A; Chouaib S; Lemonnier FA; Kosmatopoulos K
J Immunol; 2002 Jul; 169(1):575-80. PubMed ID: 12077290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]